TELA Bio (TELA)
(Real Time Quote from BATS)
$2.55 USD
+0.06 (2.41%)
Updated Oct 15, 2024 03:17 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for TELA Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 58 | 41 | 29 | 18 | 15 |
Cost Of Goods | 18 | 14 | 10 | 7 | 6 |
Gross Profit | 40 | 28 | 19 | 12 | 10 |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 67 | 49 | 37 | 29 |
Income After Depreciation & Amortization | -44 | -39 | -29 | -25 | -19 |
Non-Operating Income | 3 | -1 | 0 | 0 | 0 |
Interest Expense | 5 | 4 | 4 | 4 | 4 |
Pretax Income | -47 | -44 | -33 | -29 | -22 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -47 | -44 | -33 | -29 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -47 | -44 | -33 | -29 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -38 | -29 | -25 | -19 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -44 | -39 | -29 | -25 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 22.87 | 16.27 | 14.47 | 12.93 | 1.77 |
Diluted EPS Before Non-Recurring Items | -2.04 | -2.64 | -2.30 | -2.23 | -17.10 |
Diluted Net EPS (GAAP) | -2.04 | -2.72 | -2.30 | -2.23 | -17.10 |
Fiscal Year end for TELA Bio, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 16.09 | 16.60 | 17.00 | 15.05 |
Cost Of Goods | NA | 4.92 | 5.17 | 5.28 | 4.57 |
Gross Profit | NA | 11.17 | 11.43 | 11.72 | 10.48 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.74 | 16.26 | 24.01 | 20.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.57 | -4.83 | -12.29 | -10.19 |
Non-Operating Income | NA | 0.30 | 0.50 | 0.73 | 0.56 |
Interest Expense | NA | 1.33 | 1.33 | 1.35 | 1.33 |
Pretax Income | NA | -12.60 | -5.66 | -12.89 | -10.96 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -12.60 | -5.66 | -12.89 | -10.96 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -12.60 | -5.66 | -12.89 | -10.96 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 24.66 | 24.58 | 24.49 | 24.48 |
Diluted EPS Before Non-Recurring Items | NA | -0.51 | -0.23 | -0.53 | -0.45 |
Diluted Net EPS (GAAP) | NA | -0.51 | -0.23 | -0.50 | -0.45 |